15 September 2020

The RYR1 biobank is part of a study of the neuromuscular and multisystem features of patients with malignant hyperthermia or rhabdomyolysis related to RYR1 (ryanodine receptor type 1) variants. The main objective of the RYR1 biobank is to enable research into genetic causes and pathophysiological mechanisms, with identification of starting points for therapy. The biobank contains biomaterial (serum, heparin plasma, DNA, RNA and tissue) and clinical data from both children and adult patients.

  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Sub-biobank MEMORY

15 September 2020

The MEMORY biobank focuses on research into biomarkers for memory impairment and dementia and their validation in clinical cohorts.

read more

New colleague

15 September 2020

My name is Robbert Croes and I started mid 2020 as a data-scientist at the Radboud Biobank.

read more

ProBCI sub-biobank

15 September 2020

There is a pressing need for predictive biomarkers to personalize bladder cancer treatment.

read more

Financial regulation for sub-biobanks

15 September 2020

Sub-biobanks are not required to pay up-front for the processing and storage of biomaterials. The effectiveness of this pre-financing agreement however is dependent on adherence to the demands regarding delivery and processing according to the Radboud Biobank standard operating procedures.

read more